# TTK Healthcare (NSE: TTKHLTCARE) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/TTKHLTCARE · Pivot · prices to 22 Oct 2026

TTK Healthcare (NSE: TTKHLTCARE) closed at ₹989.70 on 22 Oct 2026, up 2.77% on the day. With a market capitalisation of ₹1,398 Cr, it ranks 1293rd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - General.

At its last close the stock traded at 21.3× trailing earnings, against a return on equity of 5.9% in FY26. Over the past year the share price has fallen 12.0%. Its 52-week range is ₹735.00 (30 Mar 2026) to ₹1,247.00 (9 Sep 2026); the last close is 20.6% below the high. Promoters held 74.56% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹989.70 |
| Market cap | ₹1,398 Cr |
| P/E (trailing) | 21.3 |
| ROE | 5.9% (FY26) |
| ROCE | 8.0% (FY26) |
| Debt to equity | 0.02 |
| 52-week high | ₹1,247.00 (9 Sep 2026) |
| 52-week low | ₹735.00 (30 Mar 2026) |
| 1-year return | −12.0% |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY26 | ₹857 Cr | ₹66 Cr |
| FY25 | ₹801 Cr | ₹82 Cr |
| FY24 | ₹753 Cr | ₹63 Cr |
| FY23 | ₹725 Cr | ₹640 Cr |
| FY22 | ₹599 Cr | ₹42 Cr |
| FY21 | ₹476 Cr | ₹46 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 74.56%
- Foreign institutions: 1.86%
- Domestic institutions: 2.19%
- Non-institutions: 21.39%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Suraksha Diagnostic](https://app.pivotnow.in/stock/SURAKSHA) | ₹289.60 | ₹1,508 Cr | 46.9 | — |
| [Astec LifeSciences](https://app.pivotnow.in/stock/ASTEC) | ₹666.40 | ₹1,485 Cr | — | — |
| [Amrutanjan Health Care](https://app.pivotnow.in/stock/AMRUTANJAN) | ₹499.00 | ₹1,443 Cr | 24.9 | — |
| [Gujarat Kidney And Super Speciality](https://app.pivotnow.in/stock/GKSL) | ₹179.49 | ₹1,415 Cr | 72.1 | — |
| [Jagsonpal Ser](https://app.pivotnow.in/stock/JAGSNPHARM) | ₹211.40 | ₹1,392 Cr | 33.4 | — |
| [Fermenta Biotech](https://app.pivotnow.in/stock/FERMENTA) | ₹455.25 | ₹1,340 Cr | — | — |

## Questions and answers

### What is the share price of TTK Healthcare today?

TTK Healthcare (NSE: TTKHLTCARE) last closed at ₹989.70 on 22 Oct 2026. Its 52-week high is ₹1,247.00 and its 52-week low is ₹735.00.

### What is the market cap of TTK Healthcare?

TTK Healthcare's market capitalisation is ₹1,398 Cr (₹1,398 Cr) at the 22 Oct 2026 close, ranking 1293rd among the NSE companies Pivot tracks.

### What is the P/E ratio of TTK Healthcare?

TTK Healthcare trades at a trailing P/E of 21.3. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 46.9.

### What is the ROE and ROCE of TTK Healthcare?

Return on equity was 5.9% in FY26 and return on capital employed was 8.0% in FY26 (standalone figures).

### Is TTK Healthcare a debt-free company?

TTK Healthcare is close to debt-free: its debt-to-equity ratio was 0.02 in FY26.

### How has TTK Healthcare stock performed over the last year?

TTK Healthcare's share price has fallen 12.0% over the past year, −1.3% over three months and −7.5% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of TTK Healthcare?

As of 30 Jun 2026: promoters 74.56%, foreign institutions 1.86%, domestic institutions 2.19%, non-institutions 21.39%.

### Who are TTK Healthcare's competitors?

The listed Pharma & Healthcare companies closest to TTK Healthcare by market cap are Suraksha Diagnostic, Astec LifeSciences, Amrutanjan Health Care, Gujarat Kidney And Super Speciality, Jagsonpal Ser and Fermenta Biotech.

### Is TTK Healthcare a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out TTK Healthcare's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on TTKHLTCARE against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.